Aura Biosciences (AURA) Enterprise Value (2021 - 2026)

Aura Biosciences (AURA) has 7 years of Enterprise Value data on file, last reported at -$84.8 million in Q1 2026.

• Quarterly Enterprise Value fell 121.82% year-over-year to -$84.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$84.8 million (down 121.82% YoY) and the FY2025 annual result came in at -$59.5 million, down 87.79% from the prior year.
• Enterprise Value retreated to -$84.8 million in Q1 2026, from -$59.5 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$20000.0 in Q4 2022 to a low of -$107.4 million in Q2 2025.
• A 5-year average of -$38.5 million and a median of -$38.2 million in 2025 frame the typical range for Enterprise Value.
• The widest YoY moves for Enterprise Value: up 99.99% in 2022, down 305450.0% in 2022.
• Tracing AURA's Enterprise Value over 5 years: stood at -$20000.0 in 2022, then tumbled by 205215.0% to -$41.1 million in 2023, then rose by 22.82% to -$31.7 million in 2024, then slumped by 87.79% to -$59.5 million in 2025, then sank by 42.47% to -$84.8 million in 2026.
• The last three Enterprise Value figures came in at -$84.8 million (Q1 2026), -$59.5 million (Q4 2025), and -$47.6 million (Q3 2025), per Business Quant data.